力生制药(002393) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 369,840,643.70, representing a 1.37% increase compared to CNY 364,845,897.95 in the same period last year[5] - Net profit attributable to shareholders decreased by 6.56% to CNY 55,275,346.71 from CNY 59,155,623.68 year-on-year[5] - Basic and diluted earnings per share decreased by 8.70% to CNY 0.21 from CNY 0.23 year-on-year[5] - Net profit for the current period was ¥56,570,945.05, slightly up from ¥55,876,040.06, indicating a growth of 1.2%[17] - Earnings per share (EPS) for the current period was ¥0.21, down from ¥0.23 in the previous period, representing a decrease of 8.7%[18] Cash Flow - The net cash flow from operating activities turned negative at CNY -977,611.58, a decline of 101.22% compared to CNY 80,435,074.93 in the previous year[5] - Cash flow from operating activities showed a net outflow of ¥977,611.58, contrasting with a net inflow of ¥80,435,074.93 in the previous period[20] - Net cash flow from investing activities was $100,676,298.73, compared to a negative cash flow of $2,980,492.07 in the previous period[21] - Total cash inflow from financing activities was $61,104,300.00, with cash outflow totaling $103,995,214.11, resulting in a net cash flow of -$42,890,914.11[21] - The net increase in cash and cash equivalents was $56,807,773.04, compared to a decrease of $16,763,965.18 in the previous period[21] - The ending balance of cash and cash equivalents was $1,651,972,826.75, down from $1,923,401,225.87 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,776,075,519.65, a slight decrease of 0.16% from CNY 5,785,511,812.28 at the end of the previous year[5] - The company's total current assets amount to ¥3,066,995,612.16, showing a slight increase from ¥3,059,714,286.07 at the beginning of the period[12] - The total liabilities amount to ¥707,592,100.78, a decrease from ¥746,527,866.55 at the beginning of the period[13] - Total liabilities decreased to ¥946,839,806.99 from ¥985,536,619.88, a reduction of 3.9%[14] - The total non-current assets are valued at ¥2,709,079,907.49, down from ¥2,725,797,526.21[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,914[9] - The largest shareholder, Tianjin Jinhao Pharmaceutical Co., Ltd., holds 50.91% of the shares, totaling 131,194,851 shares[9] - The company has a total of 1,439,980 shares held in the repurchase special account as of March 31, 2025[9] - The company has no preferred shareholders as of the reporting period[11] Expenses and Investments - Financial expenses decreased by 67.21% year-on-year, mainly due to an increase in interest income[8] - Investment income decreased by 86.68% year-on-year, as there were no equity method investment income this period[8] - Cash paid for other operating activities increased by 74.93% year-on-year, primarily due to higher R&D and sales expenses[8] - Research and development expenses rose to ¥30,749,905.79, up from ¥24,584,187.57, marking an increase of 25.2%[16] Accounting and Reporting - The company did not undergo an audit for the first quarter report[22] - The company plans to implement new accounting standards starting in 2025[22] - The report was issued by the board of directors on April 25, 2025[24] - The company is identified as Tianjin Lisheng Pharmaceutical Co., Ltd.[23]